Chinese expert consensus on clinical management of hepatopathy－related thrombocytopenia
10.3969/j.issn.1001-5256.2023.10.007
- VernacularTitle:肝病相关血小板减少症临床管理中国专家共识
- Collective Name:NATIONAL CLINICAL RESEARCH CENTER FOR INFECTIOUS DISEASES;SOCIETY OF HEPATOLOGY， BEIJING MEDICAL ASSOCIATION;TRANSLATIONAL MEDICINE BRANCH， CHINESE ASSOCIATION OF GERONTOLOGY AND GERIATRICS
- Publication Type:Journal Article
- Keywords:
Liver Diseases;
Thrombocytopenia;
Consensus
- From:
Journal of Clinical Hepatology
2023;39(10):2307-2320
- CountryChina
- Language:Chinese
-
Abstract:
Hepatopathy－related thrombocytopenia refers to a decrease in platelet count caused by liver disease or its treatment， and the incidence rate of this disease is associated with the course and severity of liver disease. The direct effect of thrombocytopenia on the clinical outcome of patients with liver disease is an increased risk of bleeding， and its indirect effect involves delay or discontinuation of treatment due to the potential risk of bleeding. The pathophysiological mechanisms of hepatopathy－related thrombocytopenia involve reduced platelet production， abnormal platelet distribution， and increased destruction or consumption. Current treatment strategies aiming at different mechanisms include thrombopoietic agents， surgery， immunosuppressants， and platelet transfusion， but their clinical application needs further standardization. In order to improve the clinical management of hepatopathy－related thrombocytopenia in China in terms of diagnosis， typing， and rational selection of treatment regimens， National Clinical Research Center for Infectious Diseases organized experts to discuss and develop these consensus statements with reference to the latest evidence of evidence－based medicine in this field.
